DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

4.19 -0.01 (-0.24%)

REAL-TIME: Last trade at

Extended Hours: $4.19 $0.00 (0.00%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

ARNA $4.19 -0.24%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.18
Previous Close $4.20
Daily Range $4.14 - $4.26
52-Week Range $3.26 - $6.59
Market Cap $1.0B
P/E Ratio -16.15
Dividend (Yield) $0.00 (0.0%)
Volume 1,617,410
Average Daily Volume 2,887,046
Current FY EPS -$0.51

Sector

Healthcare

Industry

Drug Makers

Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website: http://www.arenapharm.com/

News & Commentary

Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker

A double dose of bad news for the obesity drugmaker.

Arena: Belviq Sales Take Big Step Back - Advertising Needed

Orexigen: Contrave Sales Flattening - Europe Needed To Spur Numbers

Vivus: Qsymia Sales Win The Week, But Is It Enough?

Arena Pharmaceuticals In Good Shape Despite Flat Week In Prescriptions

Which of These Growth Stocks Is Most Worthy of Your Money?

Amarin Corp. and Arena Pharmaceuticals were once high-flying biotech stocks. Since the commercial launch of their respective flagship products, though, their shares have fallen in a big way. In this article, I consider which stock has the better chance of recapturing its former glory going forward.

Orexigen Plummets After Release Of 50% Interim Results, But Is This The End?

Why Shares of Orexigen Therapeutics, Inc. Cratered Today

Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.

5 New Biotech Developments Worth Watching

Why It's Lights Out for Orexigen Therapeutics, Inc.

Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.

See More ARNA News...

ARNA's Top Competitors

ARNA $4.19 (-0.24%)
Current stock: ARNA
AMGN $163.59 (-0.15%)
Current stock: AMGN
GILD $111.71 (0.44%)
Current stock: GILD
BIIB $398.68 (-0.62%)
Current stock: BIIB